Marinus Pharmaceuticals (MRNS) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research lowered shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a buy rating to a hold rating in a report published on Wednesday.

According to Zacks, “Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. “

A number of other equities analysts have also weighed in on the stock. Svb Leerink reiterated an outperform rating on shares of Marinus Pharmaceuticals in a research report on Wednesday, February 6th. Leerink Swann assumed coverage on shares of Marinus Pharmaceuticals in a research report on Wednesday, February 6th. They set an outperform rating and a $10.00 target price for the company. Cantor Fitzgerald set a $22.00 target price on shares of Marinus Pharmaceuticals and gave the stock a buy rating in a research report on Wednesday, December 26th. LADENBURG THALM/SH SH set a $22.00 target price on shares of Marinus Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, December 11th. Finally, Mizuho reiterated a buy rating and set a $13.00 target price on shares of Marinus Pharmaceuticals in a research report on Tuesday, December 11th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Marinus Pharmaceuticals has a consensus rating of Buy and a consensus target price of $15.21.

Shares of NASDAQ:MRNS opened at $3.49 on Wednesday. Marinus Pharmaceuticals has a twelve month low of $2.36 and a twelve month high of $10.54.

In other Marinus Pharmaceuticals news, CEO Christopher Michael Cashman sold 8,142 shares of the stock in a transaction dated Monday, January 28th. The shares were sold at an average price of $3.13, for a total transaction of $25,484.46. Following the completion of the transaction, the chief executive officer now owns 239,761 shares in the company, valued at $750,451.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.60% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in MRNS. Jennison Associates LLC lifted its holdings in shares of Marinus Pharmaceuticals by 139.4% in the fourth quarter. Jennison Associates LLC now owns 4,554,759 shares of the biopharmaceutical company’s stock worth $13,072,000 after buying an additional 2,652,236 shares in the last quarter. Partner Fund Management L.P. purchased a new stake in shares of Marinus Pharmaceuticals in the third quarter worth about $17,741,000. Credit Suisse AG lifted its holdings in shares of Marinus Pharmaceuticals by 673.8% in the third quarter. Credit Suisse AG now owns 1,033,326 shares of the biopharmaceutical company’s stock worth $10,334,000 after buying an additional 899,780 shares in the last quarter. VHCP Management III LLC purchased a new stake in shares of Marinus Pharmaceuticals in the third quarter worth about $6,723,000. Finally, Tekla Capital Management LLC lifted its holdings in shares of Marinus Pharmaceuticals by 124.8% in the fourth quarter. Tekla Capital Management LLC now owns 755,776 shares of the biopharmaceutical company’s stock worth $2,169,000 after buying an additional 419,548 shares in the last quarter. 76.60% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Further Reading: How to execute a trade ex-dividend strategy?

Get a free copy of the Zacks research report on Marinus Pharmaceuticals (MRNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.